Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MITF | O75030 | 2/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10284772 | 0.94 | APP (0.47) | APPSMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL5306486 | 0.86 | APP (0.38) | APPSMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL5378063 | 0.85 | APP (0.40) | APPSMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL2538113 | 0.85 | FEN1 (0.39) | APPSMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL2540879 | 0.83 | SMN1; SMN2 (0.41) | APPSMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL18281419 | 0.83 | SMN1; SMN2 (0.39) | APPSMN1; SMN2TP53MAPTNPC1 | |
| Bromide SCHEMBL5309783 | 0.80 | ALDH1A3 (0.41) | SMN1; SMN2TP53MAPTNPC1RAB9A | |
| SCHEMBL5305948 | 0.79 | PIK3CG (0.44) | SMN1; SMN2TP53MAPTNPC1RAB9A | |
| SCHEMBL5445185 | 0.79 | NR4A2 (0.39) | APPSMN1; SMN2TP53MAPTNPC1 | |
| SCHEMBL5304731 | 0.79 | NR4A2 (0.39) | APPSMN1; SMN2TP53MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044050-B2 | Imidazo[1,2-a]azines and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-10-25 | — | — | US | claimed |
| US-20100137321-A1 | IMIDAZO[1,2-a]AZINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | claimed |
| EP-2129676-A1 | IMIDAZO[1,2-A]AZINES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-12-09 | — | — | EP | claimed |
| WO-2008104279-A1 | IMIDAZO[1,2-A]AZINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2008-09-04 | — | — | WO | claimed |
| WO-2007034282-A2 | DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | claimed |
| US-10933049-B2 | Mobilizing agents and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-03-02 | — | — | US | disclosed |
| US-20180185328-A1 | MOBILIZING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-07-05 | — | — | US | disclosed |
| EP-3302710-A1 | MOBILIZING AGENTS AND USES THEREFOR | The University of Queensland (AU) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016191811-A1 | MOBILIZING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-12-08 | — | — | WO | disclosed |
| US-8044050-B2 | Imidazo[1,2-a]azines and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-10-25 | — | — | US | disclosed |
| US-20100137321-A1 | IMIDAZO[1,2-a]AZINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2129676-A1 | IMIDAZO[1,2-A]AZINES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008104279-A1 | IMIDAZO[1,2-A]AZINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2007034282-A2 | DIARYL-IMIDAZOLE COMPOUNDS CONDENSED WITH A HETEROCYCLE AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185328-A1 | MOBILIZING AGENTS AND USES THEREFOR | C3AR1, CSF3R, C5AR1 | APP 4680/4885SMN1; SMN2 3345/4885TP53 2107/4885 |
| US-10933049-B2 | Mobilizing agents and uses therefor | C3AR1, CSF3R, C5AR1 | APP 4680/4885SMN1; SMN2 3345/4885TP53 2107/4885 |
| US-20100137321-A1 | IMIDAZO[1,2-a]AZINES AND THEIR USE AS PHARMACEUTICALS | NOS1, NOS2, NOS3 | APP 4509/4885SMN1; SMN2 4195/4885TP53 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.